Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with transplant‐ineligible multiple myeloma: a network meta‐analysis

BACKGROUND: Multiple myeloma is a bone marrow‐based hematological malignancy accounting for approximately two per cent of cancers. First‐line treatment for transplant‐ineligible individuals consists of multiple drug combinations of bortezomib (V), lenalidomide (R), or thalidomide (T). However, acces...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cochrane Database Syst Rev
Asıl Yazarlar: Piechotta, Vanessa, Jakob, Tina, Langer, Peter, Monsef, Ina, Scheid, Christof, Estcourt, Lise J, Ocheni, Sunday, Theurich, Sebastian, Kuhr, Kathrin, Scheckel, Benjamin, Adams, Anne, Skoetz, Nicole
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons, Ltd 2019
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6876545/
https://ncbi.nlm.nih.gov/pubmed/31765002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD013487
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller